Abstract
The purpose of this phase II trial was to compare the efficacy, safety and pharmacokinetics of four irinotecan schedules for the treatment of metastatic colorectal cancer. In total, 174 5-fluorouracil pretreated patients were randomised to: arm A (n=41), 350 mg m(-2) irinotecan as a 90-min i.v. infusion q3 weeks; arm B (n=38), 125 mg m(-2) irinotecan as a 90-min i.v. infusion weekly x 4 weeks q6 weeks; arm C (n=46), 250 mg m(-2) irinotecan as a 90-min i.v. infusion q2 weeks; or arm D (n=49), 10 mg m(-2) day(-1) irinotecan as a 14-day continuous infusion q3 weeks. No significant differences in efficacy across the four arms were observed, although a shorter time to treatment failure was noted for arm D (1.7 months; P=0.02). Overall response rates were in the range 5-11%. Secondary end points included median survival (6.4-9.4 months), and time to progression (2.7-3.8 months) and treatment failure (1.7-3.2 months). Similarly, there were no significant differences in the incidence of grade 3-4 toxicities, although the toxicity profile between arms A, B, and C and D did differ. Generally, significantly less haematologic toxicity, alopecia and cholinergic syndrome were observed in arm D; however, there was a trend for increased gastro...Continue Reading
References
Dec 2, 1992·Journal of the National Cancer Institute·H A BurrisD D Von Hoff
Nov 1, 1990·Neuropeptides·G NeriG G Nussdorfer
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R OhnoM Oguro
Nov 1, 1985·Clinical Pharmacology and Therapeutics·L B Sheiner, L Z Benet
Nov 27, 1972·JAMA : the Journal of the American Medical Association
Jan 1, 1995·Cancer Chemotherapy and Pharmacology·P J HoughtonJ A Houghton
Feb 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G G ChabotR Bugat
May 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y ShimadaN Ogawa
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L RothenbergD D Von Hoff
Oct 11, 1996·Biochemical Pharmacology·L P RivoryS M Pond
Sep 1, 1996·Critical Reviews in Oncology/hematology·N MasudaM Fukuoka
Sep 1, 1996·Critical Reviews in Oncology/hematology·S O'Reilly, E K Rowinsky
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P RougierM Mahjoubi
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E GuptaM J Ratain
Aug 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H C PitotH E Windschitl
Aug 1, 1997·Naunyn-Schmiedeberg's Archives of Pharmacology·M C HaazJ Robert
Mar 21, 1998·Science·L StewartJ J Champoux
Nov 10, 1998·Lancet·D CunninghamP Herait
Jul 17, 1999·British Journal of Cancer·S GuichardP Canal
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V M HerbenW W ten Bokkel Huinink
Nov 26, 1999·Molecular Pharmacology·H M Dodds, L P Rivory
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C H TakimotoJ L Grem
Apr 1, 2000·Lancet·J Y DouillardP Rougier
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles S FuchsJ Randolph Hecht
May 20, 2004·British Journal of Cancer·T KerbuschJ H M Schellens
Citations
Jan 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lars M WagnerKatherine K Matthay
Apr 23, 2011·Sarcoma·Lars Wagner
Jun 16, 2007·Pediatric Blood & Cancer·Lars M WagnerWayne L Furman
Jan 6, 2010·Pediatric Blood & Cancer·Lars M WagnerPeter C Adamson
Mar 25, 2010·Cancer Chemotherapy and Pharmacology·Peter GibbsTracey J Brown
Jul 10, 2010·Anti-cancer Drugs·Linda J M OostendorpPetronella B Ottevanger
Jul 16, 2010·British Journal of Cancer·M CosimelliUNKNOWN Italian Society of Locoregional Therapies in Oncology (SITILO)
Mar 25, 2006·Expert Opinion on Pharmacotherapy·Shousong CaoMarwan Fakih
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guy A van HazelJacob George
Mar 23, 2012·Radiology·João Paulo da Silveira Nogueira LimaLucas Vieira dos Santos
Jul 16, 2014·Acta Oncologica·Clemens GiessenVolker Heinemann
Oct 19, 2005·Journal of Biomedical Optics·D RohlederW Petrich
Jan 28, 2017·The Cochrane Database of Systematic Reviews·Simone MocellinXavier Bonfill Cosp
Feb 1, 2011·American Journal of Clinical Oncology·Harpreet WasanRiad Salem
Jul 26, 2016·Molecular and Clinical Oncology·Yi ShaoDian-Sheng Zhong
Sep 24, 2018·International Journal of Clinical Oncology·Ayako TsuboyaYasutsuna Sasaki
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephan A VeltkampJan H M Schellens
May 10, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amanda TownsendTimothy Price
Jun 6, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproUNKNOWN European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines
Nov 26, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproUNKNOWN European Organisation for Research and Treatment of Cancer